▼ FY 2025 Summary Analysis
Annual report ending Dec 31, 2025Overview and Growth
In fiscal 2025, Azora Therapeutics, Inc. (DE) reported net loss of $7.98M. Diluted earnings per share were -$11.93, translating the period’s attributable earnings into the amount reported for each diluted share. A diluted share base of 668.63K links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. Diluted shares moved 244.5% from 194.06K in fiscal 2024, leaving the current share base higher year over year. Total assets stood at $6.67M, showing the scale of resources supporting revenue, earnings, liquidity, and financing.Profitability
Operations produced a $7.80M operating loss before non-operating and tax effects. The company ended the period with a net loss of $7.98M, extending the operating result through all remaining items. Before income taxes, the company recorded a loss of $7.98M, bridging the operating result to the final net loss. The loss-to-equity relationship was 151.2%, placing the bottom-line deficit against shareholder capital. The loss-to-assets relationship was 119.5%, placing the bottom-line deficit against the company’s resource base. The net loss narrowed to $7.98M from $13.20M in fiscal 2024.Liquidity and Capital Structure
At period end, the $6.67M asset base was financed through $1.40M of liabilities and $5.28M of equity. Current assets were $6.18M against $1.40M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. At 4.42x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. The company held $5.88M in cash and equivalents, a narrower liquidity measure than total current assets. Cash and equivalents represented 421.0% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Equity equaled 79.1% of assets, showing the shareholder-capital layer within the company’s balance sheet. Relative to total assets, liabilities measured 20.9%, complementing the separate equity-based view of the company’s capital structure. Cash and equivalents equaled 88.1% of total assets, showing the liquid cash component within the company’s broader resource base. Total assets were 32.3% higher than fiscal 2024 assets of $5.04M, measuring the company’s own balance-sheet change. Book equity was 29.7% higher than fiscal 2024 equity of $4.07M, showing how shareholder capital changed year over year. The reported cash balance changed 56.8% from $3.75M in fiscal 2024, ending higher year over year.Cash Flow and Earnings Quality
The company reported an operating cash outflow of $6.49M, rather than cash generation from operations. Cash absorbed by operations decreased from $6.92M in fiscal 2024 to $6.49M.
Based on the annual report for the fiscal year ending Dec 31, 2025.
Analysis generated .
Fundamentals Hub